SCHEMBL1107869

SCHEMBL1107869

CC1(C)c2cc(-c3nnc(-c4cccc(-c5ccccc5)n4)s3)ccc2-c2ccc(-c3nnc(-c4cccc(-c5ccccc5)n4)s3)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.46
PIM3 Q86V86 5/20 0.46
PIM2 Q9P1W9 4/20 0.46
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 2/20 0.42
HSD17B1 P14061 1/20 0.39
S1PR1 P21453 1/20 0.37
S1PR3 Q99500 1/20 0.37
RARA P10276 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36
THRB P10828 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
ATM Q13315 1/20 0.34
ASIC3 Q9UHC3 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1107948 0.91 PIM1 (0.41) PIM1PIM3PIM2HSD17B1
SCHEMBL1107936 0.91 GUSB (0.41) PIM1PIM3PIM2RAB9AHSD17B1
SCHEMBL1107935 0.88 GUSB (0.38) PIM1PIM3PIM2RAB9ARARA
SCHEMBL1107969 0.88 PIM1 (0.39) PIM1PIM3PIM2MEN1KMT2A
SCHEMBL1107977 0.88 PDK2 (0.39) PIM1PIM3PIM2RAB9ARARA
SCHEMBL1107924 0.87 PIM1 (0.36) PIM1PIM3PIM2
SCHEMBL1107952 0.87 GUSB (0.40) PIM1PIM3PIM2HSD17B1ALDH1A1
SCHEMBL1107900 0.86 KDM4E (0.48) PIM1PIM3PIM2MEN1KMT2A
SCHEMBL1107897 0.86 KDM4E (0.48) PIM1PIM3PIM2MEN1KMT2A
SCHEMBL1107912 0.85 PTPN11 (0.41) PIM1PIM3PIM2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153277-B2 Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-8153277-B2 Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 US disclosed
EP-2009013-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE Hodogaya Chemical Co., Ltd. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE OXA1L, SLCO4C1, SLCO2B1 PIM1 1477/4885PIM3 1919/4885PIM2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.